AVB-202-TT
/ Solid BioSci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 20, 2022
Prevention of Cardiac Disease Features Observed in a Conditional Knockout Mouse Model of Friedreich’s Ataxia Treated with a Novel AAV FXN Gene Therapy (AVB-202)
(ASGCT 2022)
- "Additional molecular analysis is ongoing to characterize recovery of frataxin protein levels and of mitochondrial function in heart tissue. Our findings demonstrate strong positive effects on survival and cardiac function in this FA model and support continued development of AVB-202."
Preclinical • Ataxia • Cardiomyopathy • Friedreich ataxia • Gene Therapies • Heart Failure • Movement Disorders
1 to 1
Of
1
Go to page
1